化学性质：                                                                                                             

产品描述：                                                                                                            

MSDC-0160 is a prototype mTOT-modulating insulin sensitizer [1].

MSDC-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. Co-incubation of islets with MSDC-0160 and IGF-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. MSDC-0160 at 50μM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. In addition, MSDC-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells [1].

特别提醒：